ArticlePractical laboratory medicine2026
Lipemia-induced pseudohyponatremia: Analytical bias beyond manufacturer claims.
Article in Practical laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipemia-induced sodium underestimation can introduce a clinically relevant analytic bias in sodium measurements. In this study, we aimed to evaluate the clinical impact of lipemia on sodium measurements, investigate thresholds for sodium underestimation due to lipemia, and compare manufacturer-recommended interference limits with actual clinical data. Methods: Results: Intralipid®-spiked samples exceeded the analytical and CLIA limits at lipemic indices of ∼300 and ∼500, respectively, well below manufacturer-stated thresholds (>2000). In clinical samples, sodium bias was greater than in spiked plasma where ΔNa exceeded analytical limits at L-indices >100 and CLIA TEa at >200. Conclusions: Endogenous lipemia causes clinically relevant sodium underestimation when measured via indirect ISE at lipemic indices substantially lower than manufacturer thresholds and in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.